Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01459653 · OUTCOME

Characteristics of Clusters: Liver, Renal and/or Cardiovascular Disease

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor · Source last updated 2016-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.

What was measured

Objective 7: To identify different latent clusters of end-stage cancer patients receiving chemotherapy and being treated with EP2006 for the treatment or primary or secondary prophylaxis of FN using statistical data-mining techniques to profile patients based on medical history, concomitant comorbid conditions, and current clinical status. FN=Febrile Neutropenia

Analysis population: A two-group solution converged and the groups differentiated on key baseline variables. However, the group sizes were too unevenly distributed for further analysis with the "high risk group" comprised of only 3.0% of the evaluable sample. Only patients with data in each group are analyzed for liver, renal and/or cardiovascular disease.

Groups in this outcome

EP2006 - Group 1

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

EP2006 - Group 2

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EP2006 - Group 11192
EP2006 - Group 241

Reported measurements

No Liver, renal and/or cardiovascular disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006 - Group 1931Not reportedNot reportedNot reportedNot reported
EP2006 - Group 219Not reportedNot reportedNot reportedNot reported
Liver, renal and/or cardiovascular disease (Yes)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006 - Group 1261Not reportedNot reportedNot reportedNot reported
EP2006 - Group 222Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        931
      2. group Id
        OG001
        value
        19
    title
    No Liver, renal and/or cardiovascular disease
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        261
      2. group Id
        OG001
        value
        22
    title
    Liver, renal and/or cardiovascular disease (Yes)
denoms
  1. counts
    1. group Id
      OG000
      value
      1192
    2. group Id
      OG001
      value
      41
    units
    Participants
description
Objective 7: To identify different latent clusters of end-stage cancer patients receiving chemotherapy and being treated with EP2006 for the treatment or primary or secondary prophylaxis of FN using statistical data-mining techniques to profile patients based on medical history, concomitant comorbid conditions, and current clinical status. FN=Febrile Neutropenia
groups
  1. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
    id
    OG000
    title
    EP2006 - Group 1
  2. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
    id
    OG001
    title
    EP2006 - Group 2
param Type
NUMBER
population Description
A two-group solution converged and the groups differentiated on key baseline variables. However, the group sizes were too unevenly distributed for further analysis with the "high risk group" comprised of only 3.0% of the evaluable sample. Only patients with data in each group are analyzed for liver, renal and/or cardiovascular disease.
reporting Status
POSTED
time Frame
Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.
title
Characteristics of Clusters: Liver, Renal and/or Cardiovascular Disease
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice